Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial

医学 安慰剂 冲程(发动机) 阿司匹林 人口 氯吡格雷 临床终点 风险因素 内科学 随机对照试验 麻醉 病理 机械工程 环境卫生 工程类 替代医学
作者
Mukul Sharma,Carlos A. Molina,Ḱazunori Toyoda,Dániel Bereczki,Shrikant I. Bangdiwala,Scott E. Kasner,Helmi L. Lutsep,Georgios Tsivgoulis,George Ntaios,Anna Członkowska,Ashfaq Shuaib,Pierre Amarenco,Matthias Endres,Byung‐Woo Yoon,David Tanné,Danilo Toni,Laetitia Yperzeele,Paul von Weitzel-Mudersbach,Gisele Sampaio Silva,Álvaro Avezum,Jesse Dawson,Daniel Strbian,Turgut Tatlisumak,Jens Eckstein,Ana Rodríguez-Campello,Joerg R. Weber,Else Charlotte Sandset,Nana Goar Pogosova,Li Y,Antonio Araúz,David Gailani,Vincenzo Di Lazzaro,Richard A. Bernstein,Charlotte Cordonnier,Anja Kahl,Grigor Abelian,Mark Donovan,Chahin Pachaï,Danshi Li,Graeme J. Hankey
出处
期刊:Lancet Neurology [Elsevier]
卷期号:23 (1): 46-59 被引量:25
标识
DOI:10.1016/s1474-4422(23)00403-9
摘要

Background People with factor XI deficiency have lower rates of ischaemic stroke than the general population and infrequent spontaneous bleeding, suggesting that factor XI has a more important role in thrombosis than in haemostasis. Milvexian, an oral small-molecule inhibitor of activated factor XI, added to standard antiplatelet therapy, might reduce the risk of non-cardioembolic ischaemic stroke without increasing the risk of bleeding. We aimed to estimate the dose–response of milvexian for recurrent ischaemic cerebral events and major bleeding in patients with recent ischaemic stroke or transient ischaemic attack (TIA). Methods AXIOMATIC-SSP was a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial done at 367 hospitals in 27 countries. Eligible participants aged 40 years or older, with acute (<48 h) ischaemic stroke or high-risk TIA, were randomly assigned by a web-based interactive response system in a 1:1:1:1:1:2 ratio to receive one of five doses of milvexian (25 mg once daily, 25 mg twice daily, 50 mg twice daily, 100 mg twice daily, or 200 mg twice daily) or matching placebo twice daily for 90 days. All participants received clopidogrel 75 mg daily for the first 21 days and aspirin 100 mg daily for the first 90 days. Investigators, site staff, and participants were masked to treatment assignment. The primary efficacy endpoint was the composite of ischaemic stroke or incident covert brain infarct on MRI at 90 days, assessed in all participants allocated to treatment who completed a follow-up MRI brain scan, and the primary analysis assessed the dose–response relationship with Multiple Comparison Procedure–Modelling (MCP-MOD). The main safety outcome was major bleeding at 90 days, assessed in all participants who received at least one dose of the study drug. This trial is registered with ClinicalTrials.gov (NCT03766581) and the EU Clinical Trials Register (2017-005029-19). Findings Between Jan 27, 2019, and Dec 24, 2021, 2366 participants were randomly allocated to placebo (n=691); milvexian 25 mg once daily (n=328); or twice-daily doses of milvexian 25 mg (n=318), 50 mg (n=328), 100 mg (n=310), or 200 mg (n=351). The median age of participants was 71 (IQR 62–77) years and 859 (36%) were female. At 90 days, the estimates of the percentage of participants with either symptomatic ischaemic stroke or covert brain infarcts were 16·8 (90·2% CI 14·5–19·1) for placebo, 16·7 (14·8–18·6) for 25 mg milvexian once daily, 16·6 (14·8–18·3) for 25 mg twice daily, 15·6 (13·9–17·5) for 50 mg twice daily, 15·4 (13·4–17·6) for 100 mg twice daily, and 15·3 (12·8–19·7) for 200 mg twice daily. No significant dose–response was observed among the five milvexian doses for the primary composite efficacy outcome. Model-based estimates of the relative risk with milvexian compared with placebo were 0·99 (90·2% CI 0·91–1·05) for 25 mg once daily, 0·99 (0·87–1·11) for 25 mg twice daily, 0·93 (0·78–1·11) for 50 mg twice daily, 0·92 (0·75–1·13) for 100 mg twice daily, and 0·91 (0·72–1·26) for 200 mg twice daily. No apparent dose–response was observed for major bleeding (four [1%] of 682 participants with placebo, two [1%] of 325 with milvexian 25 mg once daily, two [1%] of 313 with 25 mg twice daily, five [2%] of 325 with 50 mg twice daily, five [2%] of 306 with 100 mg twice daily, and five [1%] of 344 with 200 mg twice daily). Five treatment-emergent deaths occurred, four of which were considered unrelated to the study drug by the investigator. Interpretation Factor XIa inhibition with milvexian, added to dual antiplatelet therapy, did not substantially reduce the composite outcome of symptomatic ischaemic stroke or covert brain infarction and did not meaningfully increase the risk of major bleeding. Findings from our study have informed the design of a phase 3 trial of milvexian for the prevention of ischaemic stroke in patients with acute ischaemic stroke or TIA. Funding Bristol Myers Squibb and Janssen Research & Development.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
款解耦完成签到 ,获得积分10
1秒前
花花懿懿完成签到 ,获得积分10
3秒前
immortal完成签到,获得积分10
5秒前
鸭鸭完成签到,获得积分10
6秒前
Hello应助舒心魂幽采纳,获得10
6秒前
赫连立果完成签到 ,获得积分10
7秒前
chu完成签到,获得积分10
7秒前
大力翠阳发布了新的文献求助10
7秒前
一颗煤炭完成签到 ,获得积分10
8秒前
8秒前
搜集达人应助Okpooko采纳,获得10
10秒前
宇宙暴龙战士暴打魔法少女完成签到,获得积分10
11秒前
田様应助西门醉卉采纳,获得10
11秒前
李西瓜完成签到 ,获得积分10
15秒前
俭朴板栗完成签到,获得积分10
16秒前
寻道图强应助科研通管家采纳,获得30
17秒前
JamesPei应助科研通管家采纳,获得10
17秒前
桐桐应助科研通管家采纳,获得10
17秒前
ding应助科研通管家采纳,获得10
17秒前
科研通AI2S应助科研通管家采纳,获得10
17秒前
研友_VZG7GZ应助科研通管家采纳,获得10
17秒前
搜集达人应助科研通管家采纳,获得10
17秒前
17秒前
岳凯完成签到 ,获得积分10
18秒前
liu完成签到,获得积分20
18秒前
20秒前
20秒前
西门醉卉完成签到,获得积分10
21秒前
21秒前
21秒前
ynchaoren发布了新的文献求助10
21秒前
21秒前
金平卢仙发布了新的文献求助10
21秒前
FSS发布了新的文献求助10
24秒前
健忘的沛蓝完成签到 ,获得积分10
24秒前
西门醉卉发布了新的文献求助10
25秒前
25秒前
印第安老斑鸠完成签到,获得积分10
25秒前
无限老三发布了新的文献求助10
26秒前
高分求助中
Sustainability in Tides Chemistry 2000
Microlepidoptera Palaearctica, Volumes 1 and 3 - 13 (12-Volume Set) [German] 1122
Дружба 友好报 (1957-1958) 1000
The Data Economy: Tools and Applications 1000
Mantiden - Faszinierende Lauerjäger – Buch gebraucht kaufen 700
PraxisRatgeber Mantiden., faszinierende Lauerjäger. – Buch gebraucht kaufe 700
A Dissection Guide & Atlas to the Rabbit 600
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3100728
求助须知:如何正确求助?哪些是违规求助? 2752113
关于积分的说明 7618225
捐赠科研通 2404463
什么是DOI,文献DOI怎么找? 1275723
科研通“疑难数据库(出版商)”最低求助积分说明 616596
版权声明 599053